Norihiro Harada
Research Subjects
Norihiro Harada has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
Takeharu Kakiuchi
Central Research Laboratory, Hamamatsu Photonics K.K. Hamamatsu Japan
30 shared publicationsShingo Nishiyama
Central Research Laboratory, Hamamatsu Photonics K.K. Hamamatsu Japan
29 shared publications- Hideo Tsukada
Central Research Laboratory, Hamamatsu Photonics K. K., Hamamatsu, Japan
26 shared publications Hideo Tsukada
Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu 434-8601, Japan
25 shared publicationsHiroyuki Ohba
Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu 434-8601, Japan
23 shared publicationsDai Fukumoto
Central Research Laboratory, Hamamatsu Photonics K.K, Shizuoka, Japan
14 shared publications
Latest Publications
- Open Access
- 12 April 2025
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 144-145, 109019
Biodistribution of [18F]BCPP-BF in humans: a first-in-human positron emission tomography study
- 12 April 2025
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 144-145, 109019
Open AccessBiodistribution of [18F]BCPP-BF in humans: a first-in-human positron emission tomography study
- 4 November 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1
Advanced Leading-edge Discrimination Methods for Cherenkov-radiator-integrated Microchannel Plate Photomultiplier Tubes
Reconstruction-free direct positron emission imaging (dPEI) using two single-channel Cherenkov-radiator-integrated microchannel plate photomultiplier tubes (CRI-MCP-PMTs) was recently demonstrated. However, the 4-channel oscilloscope used in the demonstration study is not suitable for clinical systems using multichannel detector modules, therefore a dedicated multichannel data acquisition (DAQ) system with ultra-high timing resolution is required. Moreover, for developing a multi-channel ultrafast DAQ system, the leading-edge discrimination (LED) method is preferred to reduce resource usage and complexity compared to a constant-fraction discrimination method. In this study, we investigate the characteristics of CRI-MCP-PMT signals and introduce the current status of development in advanced LED methods for CRI-MCP-PMTs. Timing performance was compared at different bandwidths from 0.5 GHz to 12.5 GHz. Advanced LED methods with appropriate event classification based on the characteristics of the CRI-MCP-PMT improved timing performance. When rise time information was used for event classification, the best CTR of 28.6 ps FWHM was obtained using 10.8% of total events. In addition, a CTR of 31.3 ps FWHM was obtained with 17.3% of total events using signal fall time information for event classification.
- 4 November 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1
Advanced Leading-edge Discrimination Methods for Cherenkov-radiator-integrated Microchannel Plate Photomultiplier Tubes
Reconstruction-free direct positron emission imaging (dPEI) using two single-channel Cherenkov-radiator-integrated microchannel plate photomultiplier tubes (CRI-MCP-PMTs) was recently demonstrated. However, the 4-channel oscilloscope used in the demonstration study is not suitable for clinical systems using multichannel detector modules, therefore a dedicated multichannel data acquisition (DAQ) system with ultra-high timing resolution is required. Moreover, for developing a multi-channel ultrafast DAQ system, the leading-edge discrimination (LED) method is preferred to reduce resource usage and complexity compared to a constant-fraction discrimination method. In this study, we investigate the characteristics of CRI-MCP-PMT signals and introduce the current status of development in advanced LED methods for CRI-MCP-PMTs. Timing performance was compared at different bandwidths from 0.5 GHz to 12.5 GHz. Advanced LED methods with appropriate event classification based on the characteristics of the CRI-MCP-PMT improved timing performance. When rise time information was used for event classification, the best CTR of 28.6 ps FWHM was obtained using 10.8% of total events. In addition, a CTR of 31.3 ps FWHM was obtained with 17.3% of total events using signal fall time information for event classification.
- Open Access
- 30 March 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (5)
Brain p3‐Alcβ peptide restores neuronal viability impaired by Alzheimer's amyloid β‐peptide
We propose a new therapeutic strategy for Alzheimer's disease (AD). Brain peptide p3‐Alcβ37 is generated from the neuronal protein alcadein β through cleavage of γ‐secretase, similar to the generation of amyloid β (Aβ) derived from Aβ‐protein precursor/APP. Neurotoxicity by Aβ oligomers (Aβo) is the prime cause prior to the loss of brain function in AD. We found that p3‐Alcβ37 and its shorter peptide p3‐Alcβ9‐19 enhanced the mitochondrial activity of neurons and protected neurons against Aβo‐induced toxicity. This is due to the suppression of the Aβo‐mediated excessive Ca 2+ influx into neurons by p3‐Alcβ. Successful transfer of p3‐Alcβ9‐19 into the brain following peripheral administration improved the mitochondrial viability in the brain of AD mice model, in which the mitochondrial activity is attenuated by increasing the neurotoxic human Aβ42 burden, as revealed through brain PET imaging to monitor mitochondrial function. Because mitochondrial dysfunction is common in the brain of AD patients alongside increased Aβ and reduced p3‐Alcβ37 levels, the administration of p3‐Alcβ9‐19 may be a promising treatment for restoring, protecting, and promoting brain functions in patients with AD.
- 30 March 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (5)
Open AccessBrain p3‐Alcβ peptide restores neuronal viability impaired by Alzheimer's amyloid β‐peptide
We propose a new therapeutic strategy for Alzheimer's disease (AD). Brain peptide p3‐Alcβ37 is generated from the neuronal protein alcadein β through cleavage of γ‐secretase, similar to the generation of amyloid β (Aβ) derived from Aβ‐protein precursor/APP. Neurotoxicity by Aβ oligomers (Aβo) is the prime cause prior to the loss of brain function in AD. We found that p3‐Alcβ37 and its shorter peptide p3‐Alcβ9‐19 enhanced the mitochondrial activity of neurons and protected neurons against Aβo‐induced toxicity. This is due to the suppression of the Aβo‐mediated excessive Ca 2+ influx into neurons by p3‐Alcβ. Successful transfer of p3‐Alcβ9‐19 into the brain following peripheral administration improved the mitochondrial viability in the brain of AD mice model, in which the mitochondrial activity is attenuated by increasing the neurotoxic human Aβ42 burden, as revealed through brain PET imaging to monitor mitochondrial function. Because mitochondrial dysfunction is common in the brain of AD patients alongside increased Aβ and reduced p3‐Alcβ37 levels, the administration of p3‐Alcβ9‐19 may be a promising treatment for restoring, protecting, and promoting brain functions in patients with AD.
- Open Access
- 1 October 2020
- Published by Springer Nature in EJNMMI Research
- Vol. 10 (1) , 1-13
Synthesis and evaluation of N-isopropyl-p-[11C]methylamphetamine as a novel cerebral blood flow tracer for positron emission tomography
Introduction: Increases in fasting plasma glucose (PG) levels lead to a decrease in 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) uptake in the normal brain, especially in the precuneus, resulting in an Alzheimer’s disease (AD)-like uptake pattern. Therefore, patients with higher PG levels, such as those with diabetes, can be erroneously diagnosed with AD when positron emission tomography (PET) imaging is done using [18F]FDG, due to reduced uptake of [18F]FDG in the precuneus. To help avoid an erroneous diagnosis of AD due to differences in glucose metabolism, evaluating cerebral blood flow (CBF) in the brain is useful. However, current techniques such as single photon emission computed tomography (SPECT) and [15O]H2O PET have limitations regarding early diagnosis of AD because the images they produce are of low resolution. Here, we developed a novel CBF PET tracer that may be more useful than [18F]FDG for diagnosis of AD. Methods: We synthesized and evaluated N-isopropyl-p-[11C]methylamphetamine ([11C]4) as a carbon-11-labeled analogue of the standard CBF SPECT tracer N-isopropyl-p-[123I]iodoamphetamine. Fundamental biological evaluations such as biodistribution, peripheral metabolism in mice, and brain kinetics of [11C]4 in non-human primates with PET with successive measurement of [15O]H2O were performed. Results: [11C]4 was synthesized by methylation of the corresponding tributyltin precursor (2) with [11C]MeI in a palladium-promoted Stille cross-coupling reaction. The brain uptake of [11C]4 in mice peaked at 5–15 min after injection and then promptly decreased. Most radioactivity in the brain was detected in the unchanged form, although in the periphery, [11C]4 was rapidly metabolized to hydrophilic components. Acetazolamide (AZM) treatment significantly increased the brain uptake of [11C]4 without affecting the blood levels of radioactivity in mice. Preliminary kinetics analysis showed that the K1 of [11C]4 reflected regional CBF in a vehicle-treated monkey, but that the K1 did not reflect CBF in higher flow regions after AZM loading. Conclusion: [11C]4 is a potential novel CBF PET tracer. Further validation studies are needed before [11C]4 can be used in humans.
- 1 October 2020
- Published by Springer Nature in EJNMMI Research
- Vol. 10 (1) , 1-13
Open AccessSynthesis and evaluation of N-isopropyl-p-[11C]methylamphetamine as a novel cerebral blood flow tracer for positron emission tomography
Introduction: Increases in fasting plasma glucose (PG) levels lead to a decrease in 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) uptake in the normal brain, especially in the precuneus, resulting in an Alzheimer’s disease (AD)-like uptake pattern. Therefore, patients with higher PG levels, such as those with diabetes, can be erroneously diagnosed with AD when positron emission tomography (PET) imaging is done using [18F]FDG, due to reduced uptake of [18F]FDG in the precuneus. To help avoid an erroneous diagnosis of AD due to differences in glucose metabolism, evaluating cerebral blood flow (CBF) in the brain is useful. However, current techniques such as single photon emission computed tomography (SPECT) and [15O]H2O PET have limitations regarding early diagnosis of AD because the images they produce are of low resolution. Here, we developed a novel CBF PET tracer that may be more useful than [18F]FDG for diagnosis of AD. Methods: We synthesized and evaluated N-isopropyl-p-[11C]methylamphetamine ([11C]4) as a carbon-11-labeled analogue of the standard CBF SPECT tracer N-isopropyl-p-[123I]iodoamphetamine. Fundamental biological evaluations such as biodistribution, peripheral metabolism in mice, and brain kinetics of [11C]4 in non-human primates with PET with successive measurement of [15O]H2O were performed. Results: [11C]4 was synthesized by methylation of the corresponding tributyltin precursor (2) with [11C]MeI in a palladium-promoted Stille cross-coupling reaction. The brain uptake of [11C]4 in mice peaked at 5–15 min after injection and then promptly decreased. Most radioactivity in the brain was detected in the unchanged form, although in the periphery, [11C]4 was rapidly metabolized to hydrophilic components. Acetazolamide (AZM) treatment significantly increased the brain uptake of [11C]4 without affecting the blood levels of radioactivity in mice. Preliminary kinetics analysis showed that the K1 of [11C]4 reflected regional CBF in a vehicle-treated monkey, but that the K1 did not reflect CBF in higher flow regions after AZM loading. Conclusion: [11C]4 is a potential novel CBF PET tracer. Further validation studies are needed before [11C]4 can be used in humans.
- 28 July 2014
- Published by Wiley in Artificial Organs
- Vol. 38 (8) , 662-666
Real-Time Trafficking of PEGylated Liposomes in the Rodent Focal Brain Ischemia Analyzed by Positron Emission Tomography
A liposomal drug delivery system was previously applied to ischemic brain model rats for the treatment of brain ischemia, and we observed that 100‐nm‐sized liposomes could extravasate and accumulate in the ischemic brain region even when cerebral blood flow was markedly reduced in permanent middle cerebral artery occlusion (p‐MCAO) model rats. In the present study, we investigated the real‐time cerebral distribution of polyethylene glycol (PEG)‐modified liposomes (PEG‐liposomes) labeled with 1‐[18F]fluoro‐3,6‐dioxatetracosane in p‐MCAO rats by positron emission tomography (PET). [18F]‐Labeled PEG‐liposomes were intravenously injected into p‐MCAO rats 1 h after the onset of occlusion, and then a PET scan was performed for 2 h. The PET scan showed that the signal intensity of [18F] gradually increased in the ischemic region despite the drastic reduction in cerebral perfusion, suggesting that PEG‐liposomes had accumulated in and around the ischemic region. Therefore, drug delivery to the ischemic region by use of liposomes would be possible under ischemic conditions, and a liposomal drug delivery system could be a promising strategy for protecting the ischemic brain from damage before recovery from ischemia.
- 28 July 2014
- Published by Wiley in Artificial Organs
- Vol. 38 (8) , 662-666
Real-Time Trafficking of PEGylated Liposomes in the Rodent Focal Brain Ischemia Analyzed by Positron Emission Tomography
A liposomal drug delivery system was previously applied to ischemic brain model rats for the treatment of brain ischemia, and we observed that 100‐nm‐sized liposomes could extravasate and accumulate in the ischemic brain region even when cerebral blood flow was markedly reduced in permanent middle cerebral artery occlusion (p‐MCAO) model rats. In the present study, we investigated the real‐time cerebral distribution of polyethylene glycol (PEG)‐modified liposomes (PEG‐liposomes) labeled with 1‐[18F]fluoro‐3,6‐dioxatetracosane in p‐MCAO rats by positron emission tomography (PET). [18F]‐Labeled PEG‐liposomes were intravenously injected into p‐MCAO rats 1 h after the onset of occlusion, and then a PET scan was performed for 2 h. The PET scan showed that the signal intensity of [18F] gradually increased in the ischemic region despite the drastic reduction in cerebral perfusion, suggesting that PEG‐liposomes had accumulated in and around the ischemic region. Therefore, drug delivery to the ischemic region by use of liposomes would be possible under ischemic conditions, and a liposomal drug delivery system could be a promising strategy for protecting the ischemic brain from damage before recovery from ischemia.
- 12 June 2014
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 41 (11) , 2127-2136
Comparing amyloid-β deposition, neuroinflammation, glucose metabolism, and mitochondrial complex I activity in brain: a PET study in aged monkeys
The aim of the present study was to compare amyloid-β (Aβ) deposition, translocator protein (TSPO) activity, regional cerebral metabolic rate of glucose (rCMRglc), and mitochondrial complex I (MC-I) activity in the brain of aged monkeys. PET scans with 11C-PIB (Aβ), 18F-BCPP-EF (MC-I), 11C-DPA-713 (TSPO), and 18F-FDG (rCMRglc) were performed in aged monkeys (Macaca mulatta) in the conscious state and under isoflurane anaesthesia. 11C-PIB binding to Aβ and 11C-DPA-713 binding to TSPO were evaluated in terms of standard uptake values (SUV). The total volume of distribution (V T) of 18F-BCPP-EF and rCMRglc with 18F-FDG were calculated using arterial blood sampling. Isoflurane did not affect MC-I activity measured in terms of 18F-BCPP-EF uptake in living brain. There was a significant negative correlation between 18F-BCPP-EF binding (V T) and 11C-PIB uptake (SUVR), and there was a significant positive correlation between 11C-DPA-713 uptake (SUV) and 11C-PIB uptake. In contrast, there was no significant correlation between rCMRglc ratio and 11C-PIB uptake. 18F-BCPP-EF could be a potential PET probe for quantitative imaging of impaired MC-I activity that is correlated with Aβ deposition in the living brain.
- 12 June 2014
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 41 (11) , 2127-2136
Comparing amyloid-β deposition, neuroinflammation, glucose metabolism, and mitochondrial complex I activity in brain: a PET study in aged monkeys
The aim of the present study was to compare amyloid-β (Aβ) deposition, translocator protein (TSPO) activity, regional cerebral metabolic rate of glucose (rCMRglc), and mitochondrial complex I (MC-I) activity in the brain of aged monkeys. PET scans with 11C-PIB (Aβ), 18F-BCPP-EF (MC-I), 11C-DPA-713 (TSPO), and 18F-FDG (rCMRglc) were performed in aged monkeys (Macaca mulatta) in the conscious state and under isoflurane anaesthesia. 11C-PIB binding to Aβ and 11C-DPA-713 binding to TSPO were evaluated in terms of standard uptake values (SUV). The total volume of distribution (V T) of 18F-BCPP-EF and rCMRglc with 18F-FDG were calculated using arterial blood sampling. Isoflurane did not affect MC-I activity measured in terms of 18F-BCPP-EF uptake in living brain. There was a significant negative correlation between 18F-BCPP-EF binding (V T) and 11C-PIB uptake (SUVR), and there was a significant positive correlation between 11C-DPA-713 uptake (SUV) and 11C-PIB uptake. In contrast, there was no significant correlation between rCMRglc ratio and 11C-PIB uptake. 18F-BCPP-EF could be a potential PET probe for quantitative imaging of impaired MC-I activity that is correlated with Aβ deposition in the living brain.
- Open Access
- 3 February 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (2) , e85520
Use of Positron Emission Tomography for Real-Time Imaging of Biodistribution of Green Tea Catechin
The aim of this study was to achieve real-time imaging of the in vivo behavior of a green tea polyphenol, catechin, by positron emission tomography (PET). Positron-labeled 4″ -[11C]methyl-epigallocatechin gallate ([11C]Me-EGCG) was orally administered to rats, and its biodistribution was imaged for 60 min by using a small animal PET system. As the result, images of [11C]Me-EGCG passing through the stomach into the small intestines were observed; and a portion of it was quantitatively detected in the liver. On the other hand, intravenous injection of [11C]Me-EGCG resulted in a temporal accumulation of the labeled catechin in the liver, after which almost all of it was transferred to the small intestines within 60 min. In the present study, we succeeded in obtaining real-time imaging of the absorption and biodistribution of [11C]Me-EGCG with a PET system.
- 3 February 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (2) , e85520
Open AccessUse of Positron Emission Tomography for Real-Time Imaging of Biodistribution of Green Tea Catechin
The aim of this study was to achieve real-time imaging of the in vivo behavior of a green tea polyphenol, catechin, by positron emission tomography (PET). Positron-labeled 4″ -[11C]methyl-epigallocatechin gallate ([11C]Me-EGCG) was orally administered to rats, and its biodistribution was imaged for 60 min by using a small animal PET system. As the result, images of [11C]Me-EGCG passing through the stomach into the small intestines were observed; and a portion of it was quantitatively detected in the liver. On the other hand, intravenous injection of [11C]Me-EGCG resulted in a temporal accumulation of the labeled catechin in the liver, after which almost all of it was transferred to the small intestines within 60 min. In the present study, we succeeded in obtaining real-time imaging of the absorption and biodistribution of [11C]Me-EGCG with a PET system.
- Open Access
- 22 January 2014
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 34 (4) , 708-714
PET Imaging of Ischemia-Induced Impairment of Mitochondrial Complex I Function in Monkey Brain
To assess the capability of 18F-2-tert-butyl-4-chloro-5-{6-[2-(2-fluoroethoxy)-ethoxy]-pyridin-3-ylmethoxy}-2H-pyridazin-3-one (18F-BCPP-EF), a novel positron emission tomography (PET) probe for mitochondrial complex I (MC-I) activity, as a specific marker of ischemia-induced neuronal death without being disturbed by inflammation, translational research was conducted using an animal PET in ischemic brains of Cynomolgus monkeys ( Macaca fascicularis). Focal ischemia was induced by the right middle cerebral artery occlusion for 3 hours, then PET scans were conducted at Day-7 with 15O-gases for regional cerebral blood flow (rCBF) and regional cerebral metabolism of oxygen (rCMRO2), and 18F-BCPP-EF for MC-I with arterial blood sampling. On Day-8, the additional PET scans conducted with 11C-flumazenil (11C-FMZ) for central-type benzodiazepine receptors, 11C-PBR28 for translocator protein, and 18F-fluoro-2-deoxy-D-glucose (18F-FDG) for regional cerebral metabolic rate of glucose (rCMRglc). The total distribution volume ( VT) values of 18F-BCPP-EF showed the significant reduction in MC-I activity in the damaged area at Day-7. When correlated with rCBF and rCMRO2, the VT values of 18F-BCPP-EF provided better correlation with rCMRO2 than with rCBF. In the inflammatory regions (region of interest, ROIPBR) of the ischemic hemisphere detected with 11C-PBR28, higher 18F-FDG uptake and lower VT of 18F-BCPP-EF, 11C-FMZ, and rCMRO2 than those in normal contralateral hemisphere were observed. These results strongly suggested that 18F-BCPP-EF could discriminate the neuronal damaged areas with neuroinflammation, where 18F-FDG could not owing to its high uptake into the activated microglia.
- 22 January 2014
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 34 (4) , 708-714
Open AccessPET Imaging of Ischemia-Induced Impairment of Mitochondrial Complex I Function in Monkey Brain
To assess the capability of 18F-2-tert-butyl-4-chloro-5-{6-[2-(2-fluoroethoxy)-ethoxy]-pyridin-3-ylmethoxy}-2H-pyridazin-3-one (18F-BCPP-EF), a novel positron emission tomography (PET) probe for mitochondrial complex I (MC-I) activity, as a specific marker of ischemia-induced neuronal death without being disturbed by inflammation, translational research was conducted using an animal PET in ischemic brains of Cynomolgus monkeys ( Macaca fascicularis). Focal ischemia was induced by the right middle cerebral artery occlusion for 3 hours, then PET scans were conducted at Day-7 with 15O-gases for regional cerebral blood flow (rCBF) and regional cerebral metabolism of oxygen (rCMRO2), and 18F-BCPP-EF for MC-I with arterial blood sampling. On Day-8, the additional PET scans conducted with 11C-flumazenil (11C-FMZ) for central-type benzodiazepine receptors, 11C-PBR28 for translocator protein, and 18F-fluoro-2-deoxy-D-glucose (18F-FDG) for regional cerebral metabolic rate of glucose (rCMRglc). The total distribution volume ( VT) values of 18F-BCPP-EF showed the significant reduction in MC-I activity in the damaged area at Day-7. When correlated with rCBF and rCMRO2, the VT values of 18F-BCPP-EF provided better correlation with rCMRO2 than with rCBF. In the inflammatory regions (region of interest, ROIPBR) of the ischemic hemisphere detected with 11C-PBR28, higher 18F-FDG uptake and lower VT of 18F-BCPP-EF, 11C-FMZ, and rCMRO2 than those in normal contralateral hemisphere were observed. These results strongly suggested that 18F-BCPP-EF could discriminate the neuronal damaged areas with neuroinflammation, where 18F-FDG could not owing to its high uptake into the activated microglia.
- 21 November 2013
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 41 (4) , 755-763
Evaluation of 18F-BCPP-EF for mitochondrial complex 1 imaging in the brain of conscious monkeys using PET
We have reported on the development of a novel PET probe, 18F-2-tert-butyl-4-chloro-5-{6-[2-(2-fluoroethoxy)-ethoxy]-pyridin-3-ylmethoxy}-2H-pyridazin-3-one (18F-BCPP-EF), for quantitative imaging of mitochondrial complex 1 (MC-1) activity in the brain of the living rat. For clinical application in humans, translational research in the monkey was conducted. PET measurements with 18F-BCPP-EF were performed in young and old monkeys (Macaca mulatta) in a conscious state with arterial blood sampling. The binding specificity of 18F-BCPP-EF was evaluated with rotenone, a specific MC-1 inhibitor, in young animals. The binding (total distribution volume, V T) of 18F-BCPP-EF was calculated using Logan graphical analysis, and one-tissue compartment model (1-TC) and two-tissue compartment model (2-TC) analyses using a metabolite-corrected plasma input function. F-BCPP-EF was rapidly taken up into the brain just after intravenous injection, peaked between 10 and 20 min after injection, and was then gradually eliminated. The 2-TC analysis provided a better fit than the 1-TC analysis, and the V T values from the 2-TC analysis correlated well with those from the Logan plot. With predosing with rotenone, 18F-BCPP-EF showed a higher uptake peak in the brain, followed by more rapid elimination thereafter than in the vehicle condition, resulting in significant reductions in 2-TC V T values in all regions. In old animals, the kinetics of 18F-BCPP-EF were slightly slower with lower peak levels than in young animals, resulting age-related reductions in 18F-BCPP-EF binding in all brain regions. The present study demonstrated that 18F-BCPP-EF may be a potential PET probe for quantitative imaging MC-1 activity in the living brain using PET.
- 21 November 2013
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 41 (4) , 755-763
Evaluation of 18F-BCPP-EF for mitochondrial complex 1 imaging in the brain of conscious monkeys using PET
We have reported on the development of a novel PET probe, 18F-2-tert-butyl-4-chloro-5-{6-[2-(2-fluoroethoxy)-ethoxy]-pyridin-3-ylmethoxy}-2H-pyridazin-3-one (18F-BCPP-EF), for quantitative imaging of mitochondrial complex 1 (MC-1) activity in the brain of the living rat. For clinical application in humans, translational research in the monkey was conducted. PET measurements with 18F-BCPP-EF were performed in young and old monkeys (Macaca mulatta) in a conscious state with arterial blood sampling. The binding specificity of 18F-BCPP-EF was evaluated with rotenone, a specific MC-1 inhibitor, in young animals. The binding (total distribution volume, V T) of 18F-BCPP-EF was calculated using Logan graphical analysis, and one-tissue compartment model (1-TC) and two-tissue compartment model (2-TC) analyses using a metabolite-corrected plasma input function. F-BCPP-EF was rapidly taken up into the brain just after intravenous injection, peaked between 10 and 20 min after injection, and was then gradually eliminated. The 2-TC analysis provided a better fit than the 1-TC analysis, and the V T values from the 2-TC analysis correlated well with those from the Logan plot. With predosing with rotenone, 18F-BCPP-EF showed a higher uptake peak in the brain, followed by more rapid elimination thereafter than in the vehicle condition, resulting in significant reductions in 2-TC V T values in all regions. In old animals, the kinetics of 18F-BCPP-EF were slightly slower with lower peak levels than in young animals, resulting age-related reductions in 18F-BCPP-EF binding in all brain regions. The present study demonstrated that 18F-BCPP-EF may be a potential PET probe for quantitative imaging MC-1 activity in the living brain using PET.